Literature DB >> 18245380

Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes.

Erika Assarsson1, Jason A Greenbaum, Magnus Sundström, Lana Schaffer, Jennifer A Hammond, Valerie Pasquetto, Carla Oseroff, R Curtis Hendrickson, Elliot J Lefkowitz, David C Tscharke, John Sidney, Howard M Grey, Steven R Head, Bjoern Peters, Alessandro Sette.   

Abstract

Vaccinia virus is the prototypic orthopoxvirus and was the vaccine used to eradicate smallpox, yet the expression profiles of many of its genes remain unknown. Using a genome tiling array approach, we simultaneously measured the expression levels of all 223 annotated vaccinia virus genes during infection and determined their kinetics. For 95% of these genes, significant transcript levels were detected. Most remarkably, classification of the genes by their expression profiles revealed 35 genes exhibiting immediate-early expression. Although a similar kinetic class has been described for other virus families, to our knowledge, this is the first demonstration of its existence in orthopoxviruses. Despite expression levels higher than for genes in the other three kinetic classes, the functions of more than half of these remain unknown. Additionally, genes within each kinetic class were spatially grouped together in the genome. This genome-wide picture of transcription alters our understanding of how orthopoxviruses regulate gene expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245380      PMCID: PMC2542872          DOI: 10.1073/pnas.0711573105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  MESSENGER RNA IN CELLS INFECTED WITH VACCINIA VIRUS.

Authors:  Y BECKER; W K JOKLIK
Journal:  Proc Natl Acad Sci U S A       Date:  1964-04       Impact factor: 11.205

2.  The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion.

Authors:  Alan C Townsley; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Transcriptomal analysis of varicella-zoster virus infection using long oligonucleotide-based microarrays.

Authors:  Peter G E Kennedy; Esther Grinfeld; Marie Craigon; Klemens Vierlinger; Douglas Roy; Thorsten Forster; Peter Ghazal
Journal:  J Gen Virol       Date:  2005-10       Impact factor: 3.891

4.  Purification and identification of a vaccinia virus-encoded intermediate stage promoter-specific transcription factor that has homology to eukaryotic transcription factor SII (TFIIS) and an additional role as a viral RNA polymerase subunit.

Authors:  R Rosales; N Harris; B Y Ahn; B Moss
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

5.  Inhibition of protein synthesis by vaccinia virus. IV. The role of low-molecular-weight viral RNA in the inhibition of protein synthesis.

Authors:  R Bablanian; G Coppola; S Scribani; M Esteban
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

6.  Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules.

Authors:  Tonya J Roberts Webb; Roberta A Litavecz; Masood A Khan; Wenjun Du; Jacquelyn Gervay-Hague; Gourapura J Renukaradhya; Randy R Brutkiewicz
Journal:  Eur J Immunol       Date:  2006-10       Impact factor: 5.532

7.  Global identification of human transcribed sequences with genome tiling arrays.

Authors:  Paul Bertone; Viktor Stolc; Thomas E Royce; Joel S Rozowsky; Alexander E Urban; Xiaowei Zhu; John L Rinn; Waraporn Tongprasit; Manoj Samanta; Sherman Weissman; Mark Gerstein; Michael Snyder
Journal:  Science       Date:  2004-11-11       Impact factor: 47.728

8.  Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain.

Authors:  E Herrera; M M Lorenzo; R Blasco; S N Isaacs
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins.

Authors:  Magnus Sundstrom; Udayan Chatterji; Lana Schaffer; Sohela de Rozières; John H Elder
Journal:  Virology       Date:  2007-10-25       Impact factor: 3.616

10.  The immune epitope database and analysis resource: from vision to blueprint.

Authors:  Bjoern Peters; John Sidney; Phil Bourne; Huynh-Hoa Bui; Soeren Buus; Grace Doh; Ward Fleri; Mitch Kronenberg; Ralph Kubo; Ole Lund; David Nemazee; Julia V Ponomarenko; Muthu Sathiamurthy; Stephen Schoenberger; Scott Stewart; Pamela Surko; Scott Way; Steve Wilson; Alessandro Sette
Journal:  PLoS Biol       Date:  2005-03       Impact factor: 8.029

View more
  100 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays.

Authors:  Ann L Oberg; Neelam Dhiman; Diane E Grill; Jenna E Ryan; Richard B Kennedy; Gregory A Poland
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

3.  Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing.

Authors:  Zhilong Yang; Daniel P Bruno; Craig A Martens; Stephen F Porcella; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

4.  Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts.

Authors:  Zhilong Yang; Daniel P Bruno; Craig A Martens; Stephen F Porcella; Bernard Moss
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

5.  Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans.

Authors:  Masanori Terajima; Laura Orphin; Anita M Leporati; Pamela Pazoles; John Cruz; Alan L Rothman; Francis A Ennis
Journal:  Hum Immunol       Date:  2008-10-26       Impact factor: 2.850

6.  Deciphering poxvirus gene expression by RNA sequencing and ribosome profiling.

Authors:  Zhilong Yang; Shuai Cao; Craig A Martens; Stephen F Porcella; Zhi Xie; Ming Ma; Ben Shen; Bernard Moss
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 7.  Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens.

Authors:  Alessandro Sette; Howard Grey; Carla Oseroff; Bjoern Peters; Magdalini Moutaftsi; Shane Crotty; Erika Assarsson; Jay Greenbaum; Yohan Kim; Ravi Kolla; David Tscharke; David Koelle; R Paul Johnson; Janice Blum; Steven Head; John Sidney
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

8.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

9.  Transcriptome analysis of Frog virus 3, the type species of the genus Ranavirus, family Iridoviridae.

Authors:  S Majji; V Thodima; R Sample; D Whitley; Y Deng; J Mao; V G Chinchar
Journal:  Virology       Date:  2009-07-15       Impact factor: 3.616

10.  Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism.

Authors:  Simone Backes; Jillian S Shapiro; Leah R Sabin; Alissa M Pham; Ismarc Reyes; Bernard Moss; Sara Cherry; Benjamin R tenOever
Journal:  Cell Host Microbe       Date:  2012-08-16       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.